Company / Cash & Equivalents
Protalix BioTherapeutics, Inc. Cash & Equivalents History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$14.7M
FY2025
5-year range
$14.7M / $39.0M
FY2021-FY2025
Trend
-25.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $15M in FY2025 to $86M in FY2015.
Based on SEC 10-K filings.
$15M in FY2025 with a 10-year CAGR of -16.2%.
Declined from $24M to $15M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -5.0%
- 5-Year CAGR
- -3.8%
- 10-Year CAGR
- -16.2%
Key checks
Key Insights
- 5-year CAGR of -3.8%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 25.7% year-over-year.
- Peak cash & equivalents was recorded in FY2015.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.7M | -25.7% |
| FY2024 | $19.8M | -16.4% |
| FY2023 | $23.6M | +38.1% |
| FY2022 | $17.1M | -56.1% |
| FY2021 | $39.0M | +119.1% |
| FY2020 | $17.8M | -65.2% |
| FY2019 | $51.2M | -33.0% |
| FY2017 | $76.4M | +39.5% |
| FY2016 | $54.8M | -36.6% |
| FY2015 | $86.4M | +66.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026